Stockscreener 앱 받기
1.07
2.73%
-0.03
시장 영업 전:
1.08
0.01
+0.93%
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Upgraded to Strong-Buy at Brookline Cap M - MarketBeat
Brookline Capital Management Predicts CGTX FY2025 Earnings - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Brookline Capital Management - Defense World
Cognition Therapeutics extends expanded access program for Zervimesine (CT1812) in dementia with Lewy bodies - marketscreener.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics rises as it extends access to rare brain disorder drug - TradingView
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics (NASDAQ:CGTX) Raised to "Strong-Buy" at Brookline Capital Management - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Shares Up 4.6% – Still a Buy? - Defense World
Analyst Calls: Is Cognition Therapeutics Inc. stock a safe buy before earnings2025 Top Gainers & Precise Entry and Exit Recommendations - mfd.ru
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug - Investing.com India
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug By Investing.com - Investing.com Canada
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial - TipRanks
Cognition Therapeutics Completes FDA Meeting for Zervimesine in DLB - TradingView
Cognition Therapeutics, Inc. Discusses Phase 2b Study Plans for Zervimesine in Dementia with Lewy Bodies During FDA Type C Meeting - Quiver Quantitative
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire
Street Watch: What is LCFYWs valuation compared to sectorTrade Risk Assessment & Stock Portfolio Risk Management - baoquankhu1.vn
Gainers Report: Whats next for Cognition Therapeutics Inc stockJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - baoquankhu1.vn
Published on: 2026-01-22 00:29:52 - baoquankhu1.vn
What is the PEG ratio of Cognition Therapeutics Inc.Analyst Downgrade & Capital Efficiency Focused Ideas - bollywoodhelpline.com
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Market Catalysts: What is Cognition Therapeutics Incs debt to equity ratioInsider Selling & Capital Protection Trading Alerts - baoquankhu1.vn
Aug Catalysts: Whats the fair value of Cognition Therapeutics Inc stockPortfolio Value Summary & Real-Time Volume Spike Alerts - baoquankhu1.vn
Whats the fair value of Cognition Therapeutics Inc stock2025 Price Targets & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
CEO Moves: Is Cognition Therapeutics Inc stock a top pick in earnings season2025 Risk Factors & Precise Trade Entry Recommendations - Bộ Nội Vụ
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Cognition Therapeutics Inc. stock could outperform in 2025Earnings Recap Report & High Yield Equity Trading Tips - Улправда
Trading Recap: Will Cognition Therapeutics Inc. stock outperform growth indexes2025 Analyst Calls & Community Consensus Trade Alerts - ulpravda.ru
How resilient is Cognition Therapeutics Inc. stock in market downturnsJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда
Weekly Earnings: How Cognition Therapeutics Inc. stock reacts to oil pricesEarnings Performance Report & Stepwise Trade Signal Implementation - Улправда
Cognition Therapeutics, Inc.Common Stock (NQ: CGTX - FinancialContent
Cognition Therapeutics Announces Publication of Phase 2 Study Results for Zervimesine in Dementia with Lewy Bodies - Quiver Quantitative
Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire
DAVENPORT & Co LLC Makes New Investment in Cognition Therapeutics, Inc. $CGTX - MarketBeat
Earnings Risk: Why Cognition Therapeutics Inc stock could outperform in 2025Earnings Summary Report & Community Consensus Stock Picks - moha.gov.vn
How Cognition Therapeutics Inc. stock reacts to oil prices2025 Earnings Impact & Daily Technical Stock Forecast Reports - Улправда
Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB) - Wiley
[8-K] COGNITION THERAPEUTICS INC Reports Material Event | CGTX SEC FilingForm 8-K - Stock Titan
Cognition Therapeutics Launches New $75M ATM Offering - TipRanks
Growth Value: How Cognition Therapeutics Inc. stock reacts to oil prices2025 Short Interest & Daily Profit Maximizing Tips - Улправда
[S-3] COGNITION THERAPEUTICS INC Shelf Registration Statement | CGTX SEC FilingForm S-3 - Stock Titan
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Yahoo Finance
Cognition Therapeutics (NASDAQ:CGTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Why retail investors pile into Cognition Therapeutics Inc. stock2025 Growth vs Value & Daily Momentum Trading Reports - Newser
HC Wainwright & Co. Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
CGTX Analyst Rating: HC Wainwright & Co. Maintains Buy Rating | - GuruFocus
Why Cognition Therapeutics Inc. stock is favored by pension fundsJuly 2025 Closing Moves & Free High Return Stock Watch Alerts - Newser
Cognition Therapeutics completes enrollment in expanded access program By Investing.com - Investing.com Nigeria
Cognition Therapeutics completes enrollment in expanded access program - Investing.com India
Cognition Therapeutics Says Zervimesine Expanded Access Program Reaches Full Enrollment - marketscreener.com
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Yahoo Finance
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga
Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s - MSN
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug By Investing.com - Investing.com Nigeria
1.24%
0.19%
자본화:
|
볼륨(24시간):